Physician profile
Ben Barbot
NPI 1932550845
$6,664.71
in general payments reported to CMS, 2019-2025
43 companies · $1,694 in 2025
The $1,694 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $938 · 2022: $930 · 2023: $1,372 · 2024: $1,731 · 2025: $1,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,784 · Education: $13.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,783.66 |
| Education | $13.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,623.97 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $718.68 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Grifols USA, LLC | $497.63 | 2022-2025 | Prolastin-C Liquid |
| Vanda Pharmaceuticals INC. | $479.29 | 2024-2025 | Fanapt |
| Lilly USA, LLC | $428.28 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $369.40 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $279.35 | 2023-2024 | Arexvy, Trelegy Ellipta |
| Axsome Therapeutics, INC. | $273.37 | 2024-2025 | Auvelity, Symbravo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $254.50 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $154.77 | 2023-2025 | Rexulti |
| Mylan Specialty L.P. | $152.70 | 2021-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.71 | 2021-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $119.67 | 2024-2025 | |
| Pfizer INC. | $98.95 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.69 | 2023-2024 | Relistor |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $89.78 | 2022-2023 | |
| Alkermes, INC. | $69.00 | 2023-2025 | Aristada, Lybalvi |
| Exact Sciences Corporation | $64.68 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Nestle Healthcare Nutrition INC. | $64.61 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $61.69 | 2021-2022 | |
| Eisai INC. | $48.04 | 2021-2022 | |
| Dexcom, INC. | $46.27 | 2024-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $45.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.15 | 2021 | |
| Janssen Pharmaceuticals, INC | $41.73 | 2023 | Xarelto |
| Gilead Sciences, INC. | $38.50 | 2021-2023 | |
| Indivior INC. | $37.06 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $34.15 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $33.11 | 2024 | Voquezna |
| Biodelivery Sciences International, INC. | $32.39 | 2021 | |
| Viatris Specialty LLC | $30.76 | 2025 | Yupelri |
| Astellas Pharma US INC | $27.63 | 2021-2023 | Veozah |
| Braeburn INC. | $22.62 | 2023 | Brixadi |
| Aimmune Therapeutics, INC. | $21.71 | 2025 | Zenpep |
| Antares Pharma, INC. | $19.39 | 2023 | Nocdurna, Tlando, Xyosted |
| Neurocrine Biosciences, INC. | $19.11 | 2025 | |
| Tris Pharma INC | $18.62 | 2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $17.43 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $15.68 | 2021 | |
| Lucid Diagnostics INC. | $14.58 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.89 | 2021 | |
| Hartmann USA, INC. | $13.83 | 2025 | Zetuvit Plus 10x10 P10 |
| Organon LLC | $6.34 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ben Barbot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.